ATRA
NASDAQ
US
Atara Biotherapeutics, Inc. - Common Stock
$4.99
▼ $-0.18
(-3.48%)
Vol 47K
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$130.4M
P/E
5.6
ROE
-315.4%
Margin
15.4%
D/E
12.00
Beta
-0.40
52W
$5–$19
Wall Street Consensus
10 analysts · Apr 20262
Strong Buy
5
Buy
2
Hold
1
Sell
0
Strong Sell
70.0%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 80.0%
Next Report
May 13, 2026
EPS Estimate: $-0.41
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.41 | — | — |
| Dec 2025 | $-0.17 | $-0.25 | $-0.08 |
| Sep 2025 | $-0.88 | $-0.32 | +$0.56 |
| Jun 2025 | $-0.47 | $0.19 | +$0.66 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $32.8M | $98.1M | $17.6M | $3.5M | $1.6M |
| Net Income | — | -$12.7M | $38.0M | $2.4M | -$4.3M | -$3.4M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -315.4% | -315.4% | -315.4% | -315.4% | -315.4% |
| P/E (TTM) | 8.92 | 13.91 | 17.37 | 18.00 | 3.77 | 5.57 |
| Net Margin | 13.6% | 3.1% | 3.1% | 3.1% | 15.4% | 15.4% |
| Gross Margin | 96.8% | 81.2% | 81.2% | 81.2% | 81.6% | 81.6% |
| D/E Ratio | — | 12.00 | 12.00 | 12.00 | 12.00 | 12.00 |
| Current Ratio | 1.70 | 1.70 | 1.70 | 1.70 | 1.02 | 1.02 |
Key Ratios
ROA (TTM)
39.3%
P/S (TTM)
0.86
P/B
2.5
EPS (TTM)
$2.19
CF/Share
$-2.73
Rev Growth 3Y
+85.1%
52W High
$18.95
52W Low
$5.01
$5.01
52-Week Range
$18.95
Financial Health
Free Cash Flow
-$5.7M
Net Debt
$1.9M
Cash
$8.5M
Total Debt
$10.4M
As of Dec 31, 2025
How does ATRA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
ATRA valuation vs Biotechnology peers
P/E ratio
5.6
▼
70%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
0.9
▼
93%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
2.5
▼
0%
below
peers
(2.5)
vs Peers
vs Industry
Fair value
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
ATRA profitability vs Biotechnology peers
ROE
-315.4%
▼
369%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
15.4%
▲
105%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
81.6%
▲
4%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
39.3%
▲
184%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
ATRA financial health vs Biotechnology peers
D/E ratio
12.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.0
▼
77%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
-0.4
▼
141%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
ATRA fundamentals radar
ATRA
Peer median
Industry
ATRA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
ATRA vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
PANACEA INNOVATION LTD
Beneficial Owner of more than… · Mar 17
259163 shs
GRANT-HUERTA YANINA
Officer · Mar 09
20300 shs
NGUYEN ANHCO T
Chief Executive Officer · Mar 02
2996 shs
GRANT-HUERTA YANINA
Officer · Mar 02
2104 shs
PANACEA INNOVATION LTD
Beneficial Owner of more than… · Jan 12
80554 shs
Last 90 days
Top Holders
Top 5: 17.93%EcoR1 Capital, LLC
7.01%
$2.6M
Redmile Group, LLC
5.40%
$2.0M
Vanguard Group Inc
2.76%
$1.0M
Marshall Wace LLP
1.82%
$682K
Globeflex Capital L P
0.94%
$354K
As of Dec 31, 2025
Latest News
No related news yet